DRD2 Genotype

For decades, most antipsychotic drugs have worked by blocking or partly stimulating one receptor, and this gene holds the blueprint for it. A few newer drugs work elsewhere. That makes it one of the most studied genes in psychiatry. It's also one of the most oversold in consumer genetics.

Sequencing reads the gene letter by letter and reports which versions you carry. What the result can honestly tell you is narrower than the internet suggests. It's still worth having, mostly because it lets you stop guessing about a gene you've probably already read something alarming about.

What the Gene Codes For

DRD2 (dopamine receptor D2) sits on chromosome 11, at a spot written as 11q22 to q23, and its job is to build the D2 receptor. That receptor works like a brake. When dopamine lands on it, the cell turns its own activity down rather than up.

The densest brain clusters are in the striatum, a deep brain region that handles movement, habit, and the sense that something was worth doing. Another cluster works in the pituitary gland, where the same braking signal holds prolactin release in check. That second detail explains a lot of what happens on medication.

Block enough of these receptors and psychosis often improves, but too much blockade brings muscle stiffness and a rise in prolactin. Stimulate them, as some Parkinson's drugs do, and tremor can improve, sometimes with impulse control problems alongside it. The receptor is the pharmacology. The gene is the parts list.

The Famous A1 Allele Is in a Different Gene

Search this gene and you'll reach the A1 allele within a click or two. It comes from a marker called Taq1A, and it carries most of the folklore: reward deficiency, addiction risk, low dopamine. There's a catch. Taq1A isn't in this gene at all. It sits about 10,000 DNA letters downstream, inside a neighboring gene called ANKK1.

The two are close enough on the chromosome to be inherited together, which is why the association keeps reappearing in studies of dopamine and behavior. Brain imaging in healthy volunteers has consistently found that people carrying the A1 version have fewer D2 receptors available in the striatum. Whether that comes from the ANKK1 change itself or from something in the neighboring sequence it travels with still isn't settled, and at least one large analysis found no sign that the Taq1A change itself alters how this gene works.

Practically, this decides what to look for on your report. A sequencing panel aimed at this gene may or may not extend into the neighboring one. If the A1 allele is what you came for, confirm the marker is covered rather than assuming it is.

Alcohol and Substance Use

The modern story starts in 1990, with a report that the A1 version was more common in the brains of people who had died with severe alcoholism. It ran as the alcoholism gene. A negative study appeared in the same journal soon after, a 1993 reappraisal found no difference once the wider literature was pooled, and the single-gene version of the claim fell apart.

Then the region came back. Very large genome-wide studies, the kind that do not start by guessing which gene to test, now place this stretch of chromosome 11 among the many locations tied to alcohol use disorder. The two eras are less contradictory than they look, but the distinction matters. The specific Taq1A marker that carried the old claim doesn't reach genome-wide significance for any trait; the signal belongs to the wider region, through other variants. Which gene in that neighborhood is actually driving it isn't settled either, and some analyses favor a different nearby gene over this one. It's one small dial in a crowded stretch of chromosome, not a verdict.

So a result here won't tell you whether you'll develop a drinking problem. Family history, exposure, and the rest of your genome all carry more weight. What it can do is put a name on one piece of a pattern you may already be watching in your relatives.

Schizophrenia and Antipsychotic Medications

This is the strongest human evidence attached to the gene, and it's evidence about drugs more than about you. Large genetic studies of schizophrenia repeatedly flag this location, which is unusual and useful: one of the illness-linked loci and the classic drug target overlap.

That made it an obvious candidate for predicting who responds to antipsychotics, who develops movement side effects, and whose prolactin climbs. Decades of studies have looked. One pooled analysis did tie a different variant in this gene to treatment response while finding nothing for Taq1A, and the results overall have been inconsistent enough that no prescribing-genetics guideline currently recommends genotyping this gene before choosing an antipsychotic.

That's where it stands today. If you're on a dopamine-blocking medication, the genotype is context, not a dosing instruction. The labs that track what the drug is actually doing to you tell you far more.

ADHD and the Dopamine Story

Dopamine genes and ADHD have been linked in the popular telling for decades, and this gene gets named constantly. The small candidate studies behind that claim haven't been supported by larger work. Related receptor genes, DRD4 in particular, held up better in early pooled analyses, though the big genome-wide studies haven't confirmed them either.

ADHD is polygenic in the fullest sense: many common variants with tiny individual effects, plus environment. No dopamine receptor genotype diagnoses it, rules it out, or predicts whether stimulants will help.

A One-Time Result, Then Years of Context

Your genotype was fixed before you were born and won't move. There's no trend to follow, no retest interval, no reason to check again after a change in how you live. Sequence it once, keep the report, and let it inform decisions over years.

What does need tracking is everything downstream. If you take a medication that blocks these receptors, weight, glucose, and lipids are the numbers that show how your body is handling it: at least yearly once stable, and sooner after a start or dose change. Prolactin is usually checked before starting, and after that guidelines split. Some ask for it on the same yearly schedule, others only when symptoms show up or when you're on one of the drugs most likely to raise it, such as risperidone or paliperidone.

If alcohol is the family concern, liver enzymes and blood counts track harm from the thing itself rather than the predisposition. The genotype is the constant. Everything you can act on gets measured somewhere else.

When a Genetic Result Can Mislead

• Panel coverage: sequencing only reports what it was built to read. Finding nothing notable here doesn't rule out rare changes elsewhere, and the panel may not reach the neighboring marker most people came looking for.
• Ancestry: how common these versions are differs sharply between populations, and most of the behavioral research was done in people of European ancestry. A version that's common in one group can be rare in another, and studies done in one ancestry don't always transfer cleanly.
• Variants nobody has classified: sequencing turns up rare changes that haven't been seen often enough to interpret. Labs report these as uncertain. Uncertain means uncertain, not mildly bad.
• Somatic changes: this test is meant to read inherited DNA. A change found only in a tumor, or a low-level signal from abnormal blood cells, doesn't automatically mean you were born with it.
• Consumer chips versus clinical sequencing: a direct-to-consumer raw data file reads single spots and can miscall any one of them. If a consumer report is what's driving your worry, confirm that exact position with clinical-grade testing.

What to Do With a Flagged Result

Start by asking whether the result could change anything. For most people the answer is no, and stopping there is a legitimate choice. If it could change something, confirm it by a second method before acting, particularly when the original call came from a consumer chip.

Then look sideways rather than further into this one gene. If you take or are about to start an antipsychotic or a dopamine agonist, pair this with a metabolic panel, and with prolactin if you have symptoms that fit or you're on one of the drugs that raises it most. Bring the genotype to your prescribing psychiatrist as background rather than as a request to switch drugs. If the worry is medication choice, drug-metabolism genotyping will tell you more about how you handle specific medications than this gene does.

If the worry is addiction risk in your family, the useful next data are your own pattern of use and downstream labs, not more single dopamine-gene claims. A genetic counselor is worth an hour if the lab flagged something it couldn't classify, or if the result is changing how you think about risk in your children. And tell your siblings and parents what you found. They carry versions of the same sequence, and they may want their own answer.